After a successful phase I study of pharmacokinetics and pharmacodynamics of recombinant human (rh)ACE2 in healthy volunteers (Haschke et al., 2013), a clinical trial in patients with ARDS was terminated prematurely because the predefined effects on outcome were not achieved (Khan et al., 2017). Here, ACE2 is linked to acute respiratory distress syndrome.